{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:17:15Z","timestamp":1761895035431},"reference-count":11,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2010,2,20]],"date-time":"2010-02-20T00:00:00Z","timestamp":1266624000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2010,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Objectives:\u2002<\/jats:bold> Lenalidomide and dexamethasone (LenDex) is an active regimen for relapsed\/refractory multiple myeloma (MM). However, there is limited data for the effect of LenDex on renal impairment (RI) and on renal reversibility.<\/jats:p><jats:p><jats:bold>Patients &amp; Methods:\u2002<\/jats:bold> Fifty consecutive patients with relapsed\/refractory MM received LenDex in 28\u2010d cycles. Median lines of previous therapies were 2 (range: 1\u20136). Lenalidomide was administered on days 1\u201321 according to creatinine clearance (CrCl), while dexamethasone was given at a dose of 40\u2003mg on days 1\u20134 and 15\u201318 for the first four cycles and only on days 1\u20134 thereafter.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> Twelve patients (24%) had RI at baseline, defined as CrCl &lt;\u200350\u2003mL\/min. Most patients were pretreated with either thalidomide or bortezomib and &gt;\u200350% of them were refractory to both drugs. At least partial response was documented in 60.5% and 58% of patients with and without RI. Median progression\u2010free survival (PFS) and overall survival (OS) for all patients was 9 and 16\u2003months, respectively. RI was not associated with an inferior PFS or OS. There were no differences in the incidence of adverse events among patients with and without RI. Three of 12 patients with RI (25%) achieved complete renal response and two (16%) achieved minor renal response with LenDex.<\/jats:p><jats:p><jats:bold>Conclusions:\u2002<\/jats:bold> We conclude that LenDex is an active treatment even in heavily pretreated MM. With dosing of lenalidomide according to renal function, LenDex can be administered to patients with RI (who may not have other treatment options) without excessive toxicity. Furthermore, LenDex may improve the renal function in approximately 40% of patients with RI.<\/jats:p>","DOI":"10.1111\/j.1600-0609.2010.01432.x","type":"journal-article","created":{"date-parts":[[2010,2,20]],"date-time":"2010-02-20T13:28:47Z","timestamp":1266672527000},"page":"1-5","source":"Crossref","is-referenced-by-count":32,"title":["Lenalidomide and dexamethasone for the treatment of refractory\/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment"],"prefix":"10.1111","volume":"85","author":[{"given":"Meletios A.","family":"Dimopoulos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Christoulas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Roussou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Efstathios","family":"Kastritis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalini","family":"Migkou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Gavriatopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charis","family":"Matsouka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Despoina","family":"Mparmparoussi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erasmia","family":"Psimenou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irini","family":"Grapsa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleni","family":"Efstathiou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,6,15]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070594"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070596"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25139"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270007309563"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404284"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11463"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2009.n.059"},{"issue":"1","key":"e_1_2_5_9_2","article-title":"Use of lenalidomide (Revlimid\u00ae)\u2003\u00b1\u2003corticosteroids in relapsed\/refractory multiple myeloma patients with elevated baseline serum creatinine levels","volume":"108","author":"Reece DE","year":"2006","journal-title":"Blood"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06698.x"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70284-0"},{"key":"e_1_2_5_12_2","first-page":"29","article-title":"Activity and safety of lenalidomide and dexamethasone in multiple myeloma patients with advanced renal failure: a Spanish multicenter retrospective study","volume":"11","author":"Roig M","year":"2010","journal-title":"Lancet Oncol"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2010.01432.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.2010.01432.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T18:30:08Z","timestamp":1698777008000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2010.01432.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,15]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["10.1111\/j.1600-0609.2010.01432.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2010.01432.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,15]]}}}